Loading…
Employees: 2,849
Size WELL LEAD MEDICAL (603309.SS) is a China Health Care company (Medical Specialties) with a market value of $486M, the 3922nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥11.10 on 6 Nov 2026.
Performance Over six months the shares fell 18.8%, against -13.4% for the median peer and -16.4% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 1.4% over the last twelve months (peer median +1.5%); the operating margin is 15.0% (peer median 4.4%).
Valuation It trades at 12.2× forward earnings against a peer median of 18.5× (3rd cheapest of 10).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.6 points above its cost of capital (5.3% WACC).
Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.66B | CN¥1.62B | CN¥1.50B | CN¥1.38B | CN¥1.35B |
| Revenue growth | — | +8% | +9% | +2% | — |
| Gross profit | CN¥757M | CN¥686M | CN¥631M | CN¥594M | CN¥544M |
| EBITDA | n/a | CN¥359M | CN¥325M | CN¥298M | CN¥263M |
| Net income | CN¥33.0M | CN¥76.3M | CN¥219M | CN¥192M | CN¥167M |
| Free cash flow | CN¥238M | CN¥127M | -CN¥2.21M | -CN¥124M | CN¥219M |
| Capital expenditure | CN¥168M | CN¥206M | CN¥316M | CN¥358M | CN¥181M |
| Total debt | CN¥632M | CN¥619M | CN¥513M | CN¥397M | CN¥292M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603309.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.4% | -6.9% | 5th highest of 21 |
| 6-month return | -18.8% | -13.4% | 7th lowest of 21 |
| Distance from 52-week high | -32.4% | -35.1% | 10th highest of 21 |
| Revenue growth (TTM) | +1.4% | +1.5% | 11th highest of 21 |
| Operating margin | 15.0% | 4.4% | 3rd highest of 21 |
| Forward P/E | 12.2× | 18.5× | 3rd cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | -5.6% | 11.5% | least demanding of 14 |
| Growth delivered (Del g) | +7.7% | +0.4% | 6th highest of 14 |
| Hurdle (Req g minus delivered) | -13.3 pp | +6.6 pp | 3rd least demanding of 14 |
| ROIC minus cost of capital | +6.6 pp | -3.8 pp | 3rd highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| WELL LEAD MEDICAL 603309.SS | China | $486M | -19% | +1% | 15% | 12.2× | -5.6% | +7.7% |
| CellaVision CEVI.ST | Sweden | $485M | +68% | +2% | 23% | 31.8× | 6.5% | +10.0% |
| MiMedx MDXG | United States | $483M | -8% | -23% | -8% | 59.1× | 11.5% | +11.0% |
| Beijing Leadman Biochemistry 300289.SZ | China | $483M | -11% | -6% | -12% | n/a | 35.5% | -6.9% |
| AngioDynamics ANGO | United States | $493M | +5% | +8% | -6% | n/a | n/a | n/a |
| China Isotope & Radiation 1763.HK | Hong Kong | $478M | -38% | -5% | 13% | 6.7× | n/a | n/a |
| Revenio REG1V.HE | Finland | $494M | -22% | +16% | 14% | 18.5× | 19.3% | +12.4% |
| Shofu 7979.T | Japan | $475M | +27% | +7% | 14% | 12.2× | n/a | n/a |
| Shanghai Kindly Enterprises Development 603987.SS | China | $474M | -14% | 0% | 11% | n/a | 3.8% | -2.8% |
| Guangdong Shirongzhaoye 002016.SZ | China | $473M | -28% | -31% | 3% | n/a | 22.2% | -11.7% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $499M | -14% | -9% | -51% | n/a | n/a | n/a |
| Huaren Pharmaceutical 300110.SZ | China | $472M | -16% | -3% | 6% | n/a | 6.7% | +0.3% |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $471M | +40% | +5% | 11% | 38.6× | 22.1% | +2.2% |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $470M | +35% | -5% | 2% | n/a | 42.6% | +0.4% |
| Jenscare Scientific 9877.HK | Hong Kong | $463M | -32% | +993% | -106% | n/a | n/a | n/a |
| AVITA Medical RCEL | United States | $513M | +304% | +1% | -47% | n/a | n/a | n/a |
| Delcath Systems DCTH | United States | $518M | +30% | +36% | -2% | n/a | 10.1% | +120.2% |
| Guangdong Biolight Meditech 300246.SZ | China | $519M | -23% | +4% | -9% | n/a | 14.8% | -4.7% |
| Eiken Chemical 4549.T | Japan | $454M | -29% | +4% | 6% | 23.6× | n/a | n/a |
| Hunan Sundy Science and Technology 300515.SZ | China | $453M | -13% | +10% | 27% | 14.1× | 0.9% | +15.6% |
| Hangzhou Alltest Biotech 688606.SS | China | $521M | -15% | 0% | 13% | 7.4× | -3.9% | -4.3% |